Editorial: Multi-omics approaches for decoding heterogeneity in cancer immunotherapy

Aimin Jiang; Ying Liu; Ouyang Chen; Zhigang Liu; Hongzhou Cai; Linhui Wang; Lin Qi

doi:10.3389/fphar.2023.1324212

Editorial: Multi-omics approaches for decoding heterogeneity in cancer immunotherapy

Front Pharmacol. 2023 Nov 3:14:1324212. doi: 10.3389/fphar.2023.1324212. eCollection 2023.

Authors

Aimin Jiang¹, Ying Liu¹, Ouyang Chen², Zhigang Liu³, Hongzhou Cai⁴, Linhui Wang¹, Lin Qi^{5

6}

Affiliations

¹ Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China.
² Department of Cell Biology, Duke University Medical Center, Durham, NC, United States.
³ Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, Dongguan, Guangdong, China.
⁴ Department of Urology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
⁵ Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
⁶ Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Changsha, Hunan, China.

No abstract available

Keywords: cancer immunotherapy; multi-omics; personalized medicine; tumor heterogeneity; tumor microenvironment.

Publication types

Editorial

Grants and funding

The authors declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the National Natural Science Foundation of China (81902560, 81730073, and 81872074), the Fundamental Research Funds for the Central Universities of Central South University (2023ZZTS0024) and the Postgraduate Scientific Research Innovation Project of Hunan Province (CX20230114).